Lunai Bioworks Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Lunai Bioworks Inc. (LNAI) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$5.27 million for the 6-month period ending 2020-12-31, per its 10-Q filed 2021-02-16.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2021-02-16
- Lunai Bioworks Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2020-12-31 was -$2.54M.
- Lunai Bioworks Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2020-09-30 was -$2.73M.
- Lunai Bioworks Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2020-06-30 was -$2.24M, a 211.58% decline year-over-year.
- Lunai Bioworks Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2020-03-31 was $2.31M.
- Lunai Bioworks Inc. cash and cash equivalents, period increase (decrease) for fiscal 2020 was -$3.59M.
- Lunai Bioworks Inc. cash and cash equivalents, period increase (decrease) for fiscal 2019 was -$3.32M, a 128.46% decline from fiscal 2018.
- Lunai Bioworks Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $11.66M, a 197.55% increase from fiscal 2017.
- Lunai Bioworks Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $3.92M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 23 month | Cash and Cash Equivalents, Period Increase (Decrease) 26 month | Cash and Cash Equivalents, Period Increase (Decrease) 29 month | Cash and Cash Equivalents, Period Increase (Decrease) 35 month |
|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | -$2.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-16 | -$5.27M 10-Q · filed 2021-02-16 | -$7.51M derived: sum of 3 quarters · filed 2021-02-16 | -$5.20M derived: sum of 4 quarters · filed 2021-02-16 | ||||
| 2020-09-30 | -$2.73M 10-Q · filed 2020-11-12 | -$4.97M derived: sum of 2 quarters · filed 2020-11-12 | -$2.66M derived: sum of 3 quarters · filed 2020-11-12 | -$5.17M derived: sum of 4 quarters · filed 2021-02-16 | ||||
| 2020-06-30 | -$2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2020-09-23 | $69.68K derived: sum of 2 quarters · filed 2020-09-23 | -$2.44M derived: sum of 3 quarters · filed 2021-02-16 | -$3.59M 10-K · filed 2020-09-23 | ||||
| 2020-03-31 | $2.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-11 | -$199.09K derived: sum of 2 quarters · filed 2021-02-16 | -$1.34M 10-Q · filed 2020-05-11 | $666.97K derived: sum of 4 quarters · filed 2021-02-16 | ||||
| 2019-12-31 | -$2.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-16 | -$3.66M 10-Q · filed 2021-02-16 | -$1.65M derived: sum of 3 quarters · filed 2021-02-16 | -$4.61M derived: sum of 4 quarters · filed 2021-02-16 | ||||
| 2019-09-30 | -$1.14M 10-Q · filed 2020-11-12 | $866.05K derived: sum of 2 quarters · filed 2020-11-12 | -$2.10M derived: sum of 3 quarters · filed 2020-11-12 | -$2.27M derived: sum of 4 quarters · filed 2020-11-12 | ||||
| 2019-06-30 | $2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2020-09-23 | -$958.02K derived: sum of 2 quarters · filed 2020-09-23 | -$1.12M derived: sum of 3 quarters · filed 2020-09-23 | -$3.32M 10-K · filed 2020-09-23 | ||||
| 2019-03-31 | -$2.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-11 | -$3.13M derived: sum of 2 quarters · filed 2020-05-11 | -$5.33M 10-Q · filed 2020-05-11 | -$6.75M derived: sum of 4 quarters · filed 2020-05-11 | ||||
| 2018-12-31 | -$164.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-10 | -$2.36M 10-Q · filed 2020-02-10 | -$3.78M derived: sum of 3 quarters · filed 2020-02-10 | $10.93M derived: sum of 4 quarters · filed 2020-02-10 | ||||
| 2018-09-30 | -$2.20M 10-Q · filed 2019-11-13 | -$3.61M derived: sum of 2 quarters · filed 2019-11-13 | $11.10M derived: sum of 3 quarters · filed 2019-11-13 | $10.46M derived: sum of 4 quarters · filed 2019-11-13 | ||||
| 2018-06-30 | -$1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-30 | $13.29M derived: sum of 2 quarters · filed 2019-09-30 | $12.66M derived: sum of 3 quarters · filed 2019-09-30 | $11.66M 10-K · filed 2019-09-30 | ||||
| 2018-03-31 | $14.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-16 | $14.07M derived: sum of 2 quarters · filed 2019-05-16 | $13.08M 10-Q · filed 2019-05-16 | $16.98M derived: sum of 4 quarters · filed 2019-05-16 | ||||
| 2017-12-31 | -$638.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-13 | -$1.64M 10-Q · filed 2019-02-13 | $2.27M derived: sum of 3 quarters · filed 2019-02-13 | $2.19M derived: sum of 4 quarters · filed 2019-02-13 | ||||
| 2017-09-30 | -$997.05K 10-Q · filed 2018-11-14 | $2.91M derived: sum of 2 quarters · filed 2018-11-14 | $2.83M derived: sum of 3 quarters · filed 2018-11-14 | $2.91M derived: sum of 4 quarters · filed 2018-11-14 | ||||
| 2017-06-30 | $3.91M derived: 10-K 12 month − 10-Q 9 month · filed 2018-10-01 | $3.82M derived: sum of 2 quarters · filed 2018-10-01 | $3.91M derived: sum of 3 quarters · filed 2018-10-01 | $3.92M 10-K · filed 2018-10-01 | ||||
| 2017-03-31 | -$83.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-15 | $2.02K derived: sum of 2 quarters · filed 2018-05-15 | $10.33K 10-Q · filed 2017-05-15 | -$117.52K derived: sum of 4 quarters · filed 2018-05-15 | ||||
| 2016-12-31 | $85.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-09 | $94.24K 10-Q · filed 2018-02-09 | -$33.62K derived: sum of 3 quarters · filed 2018-02-09 | -$413.65K derived: sum of 4 quarters · filed 2018-02-09 | ||||
| 2016-09-30 | $8.31K 10-Q · filed 2017-11-20 | -$119.55K derived: sum of 2 quarters · filed 2017-11-20 | -$499.58K derived: sum of 3 quarters · filed 2017-11-20 | -$1.02M derived: sum of 4 quarters · filed 2017-11-20 | ||||
| 2016-06-30 | -$127.85K derived: 10-K 12 month − 10-Q 9 month · filed 2017-11-20 | -$507.89K derived: sum of 2 quarters · filed 2017-11-20 | -$1.02M derived: sum of 3 quarters · filed 2017-11-20 | -$397.78K 10-K · filed 2017-11-20 | ||||
| 2016-03-31 | -$380.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-13 | -$896.90K derived: sum of 2 quarters · filed 2017-02-14 | -$269.92K 10-Q · filed 2017-05-15 | -$3.28M derived: sum of 4 quarters · filed 2017-02-14 | ||||
| 2015-12-31 | -$516.86K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-14 | $110.11K 10-Q · filed 2017-02-14 | -$2.90M derived: sum of 3 quarters · filed 2017-02-14 | -$2.48M derived: sum of 4 quarters · filed 2017-02-14 | ||||
| 2015-09-30 | $626.98K 10-Q · filed 2016-11-14 | -$2.39M derived: sum of 2 quarters · filed 2016-11-14 | -$1.96M derived: sum of 3 quarters · filed 2016-11-14 | $450.38K derived: sum of 4 quarters · filed 2016-11-14 | ||||
| 2015-06-30 | -$3.01M derived: 10-K 6 month − 10-Q 3 month · filed 2016-09-28 | -$2.59M 10-K · filed 2016-09-28 | -$176.60K derived: sum of 3 quarters · filed 2016-09-28 | $240.12K derived: sum of 4 quarters · filed 2016-09-28 | ||||
| 2015-03-31 | $426.10K 10-Q · filed 2015-05-13 | $2.84M derived: sum of 2 quarters · filed 2016-02-12 | $3.25M 10-Q · filed 2016-05-13 | $3.38M derived: sum of 4 quarters · filed 2016-02-12 | ||||
| 2014-12-31 | $2.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-12 | $2.83M 10-Q · filed 2016-02-12 | $2.95M derived: sum of 3 quarters · filed 2016-02-12 | $2.99M 10-K · filed 2016-09-28 | ||||
| 2014-09-30 | $416.72K 10-Q · filed 2015-11-13 | $543.27K derived: sum of 2 quarters · filed 2015-11-13 | $578.95K 10-Q · filed 2014-11-13 | $578.97K derived: sum of 4 quarters · filed 2015-11-13 | ||||
| 2014-06-30 | $126.55K derived: 10-KT 6 month − 10-Q 3 month · filed 2015-09-28 | $162.23K 10-KT · filed 2015-09-28 | $162.25K derived: sum of 3 quarters · filed 2015-09-28 | $162.03K derived: sum of 4 quarters · filed 2015-09-28 | ||||
| 2014-03-31 | $35.68K 10-Q · filed 2015-05-13 | $35.70K derived: sum of 2 quarters · filed 2015-05-13 | $35.48K derived: sum of 3 quarters · filed 2015-05-13 | $28.96K derived: sum of 4 quarters · filed 2015-05-13 | ||||
| 2013-12-31 | $22.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-02-11 | -$197.00 derived: sum of 2 quarters · filed 2014-02-11 | -$6.72K 10-Q · filed 2014-02-11 | $14.41K 10-KT · filed 2015-09-28 | $22.00 10-Q · filed 2014-02-11 | |||
| 2013-09-30 | -$219.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-11-15 | -$6.74K 10-Q · filed 2013-11-15 | $32.59K 10-Q · filed 2014-11-13 | -$5.59K derived: sum of 4 quarters · filed 2014-05-14 | ||||
| 2013-06-30 | -$6.53K 10-Q · filed 2013-08-15 | $27.88K 10-Q · filed 2014-08-14 | -$5.37K derived: sum of 3 quarters · filed 2014-05-14 | $219.00 10-Q · filed 2013-08-15 | ||||
| 2013-03-31 | $3.29K 10-Q · filed 2014-05-14 | $1.15K derived: sum of 2 quarters · filed 2014-05-14 | $6.41K 10-K · filed 2013-07-16 | $6.74K 10-K · filed 2013-07-16 | ||||
| 2012-12-31 | -$2.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-02-11 | -$178.00 10-Q · filed 2014-02-11 | -$246.60K 10-Q · filed 2014-08-14 | $158.00 10-Q · filed 2013-02-14 | ||||
| 2012-09-30 | $1.96K 10-Q · filed 2013-11-15 | |||||||
| 2012-03-31 | $213.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-07-16 | $336.00 10-K · filed 2013-07-16 | ||||||
| 2011-12-31 | $123.00 10-Q · filed 2013-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |